- Home
- GEVO vs GOSS Comparison
GEVO vs GOSS Comparison
Compare GEVO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- GOSS
- Stock Information
- Founded
- GEVO 2005
- GOSS 2015
- Country
- GEVO United States
- GOSS United States
- Employees
- GEVO N/A
- GOSS N/A
- Industry
- GEVO Major Chemicals
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- GOSS Health Care
- Exchange
- GEVO Nasdaq
- GOSS Nasdaq
- Market Cap
- GEVO 418.4M
- GOSS 347.8M
- IPO Year
- GEVO 2011
- GOSS 2019
- Fundamental
- Price
- GEVO $1.73
- GOSS $2.47
- Analyst Decision
- GEVO Buy
- GOSS Strong Buy
- Analyst Count
- GEVO 2
- GOSS 4
- Target Price
- GEVO $7.58
- GOSS $8.50
- AVG Volume (30 Days)
- GEVO 9.3M
- GOSS 3.1M
- Earning Date
- GEVO 08-11-2025
- GOSS 08-05-2025
- Dividend Yield
- GEVO N/A
- GOSS N/A
- EPS Growth
- GEVO N/A
- GOSS N/A
- EPS
- GEVO N/A
- GOSS N/A
- Revenue
- GEVO $80,187,000.00
- GOSS $40,237,000.00
- Revenue This Year
- GEVO $909.99
- GOSS N/A
- Revenue Next Year
- GEVO $22.37
- GOSS $30.65
- P/E Ratio
- GEVO N/A
- GOSS N/A
- Revenue Growth
- GEVO 341.75
- GOSS N/A
- 52 Week Low
- GEVO $0.67
- GOSS $0.66
- 52 Week High
- GEVO $3.39
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- GEVO 57.77
- GOSS 68.08
- Support Level
- GEVO $1.54
- GOSS $2.38
- Resistance Level
- GEVO $1.86
- GOSS $2.65
- Average True Range (ATR)
- GEVO 0.14
- GOSS 0.15
- MACD
- GEVO 0.01
- GOSS 0.03
- Stochastic Oscillator
- GEVO 31.15
- GOSS 76.67
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.